Advances in Genomic Profiling and Risk Stratification in Acute Myeloid Leukemia.
Daniel R Richardson, Matthew C Foster, Catherine C Coombs and 1 others
PMID 31759819WHAT IT FOUND
Genetic profiling in AML changes risk categories, chemotherapy and transplant choices.
Nurses may need to manage a several-day delay with hydroxyurea, minimal residual disease monitoring, and targeted therapy side effects such as differentiation syndrome.
Key findings
01Genetic profiling stratifies AML into favorable, intermediate or adverse risk groups that inform prognosis.
02Some mutations have treatment implications, including FLT3 inhibitors such as midostaurin and gilteritinib, and IDH inhibitors such as ivosidenib and enasidenib.
03IDH inhibitors can cause differentiation syndrome, and about 12% of patients treated with enasidenib develop it, requiring urgent corticosteroids.
STILL TO COME
How it was doneWhat they foundWhat it means for RNs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The article is a narrative review, not a primary study, so it does not test a nursing intervention or provide new outcome data. The illustrative case cannot show what happens in most patients. The article does not present a systematic search or quality appraisal of the cited studies. MRD-directed therapy is described as often suggested, but randomized trials showing benefit are lacking. The prognostic value of IDH mutations is not settled, and they are not included in current risk-stratification models.
Declared interests
No conflicts-of-interest or funding declaration is included in the supplied text. The publication types list U.S. government Public Health Service research support.
The easy way to misread this
Do not read this review as proof that genomic profiling improves survival. It summarizes published evidence and a case, and it does not test a nursing intervention or report original outcomes.